Vir Biotechnology, Inc. (VIR)
NASDAQ:VIR
Want to see VIR full AI Analyst Report?
VIR Stock Chart & Stats
$10.75
$5.76(73.00%)
At close: 4:00 PM EST
$10.75
$5.76(73.00%)
Day’s Range― - ―
52-Week Range$4.16 - $11.66
Previous CloseN/A
Volume25.73M
Average Volume (3M)1.64M
Market Cap
$1.48B
Enterprise Value$1.42B
Total Cash (Recent Filing)$472.36M
Total Debt (Recent Filing)$86.64M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Jul 30, 2026EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.13
Shares Outstanding168,651,980
10 Day Avg. Volume1,718,796
30 Day Avg. Volume1,637,155
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.09
Price to Sales (P/S)12.18
P/FCF Ratio-2.11
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue21.67
Enterprise Value/Gross Profit7.87
Enterprise Value/Ebitda-3.18
Forecast
1Y Price Target
$20.86Price Target Upside94.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.93
Revenue Forecast (FY)$161.89M
Bulls Say, Bears Say
Bulls Say
Balance Sheet / RunwaySubstantial cash balances and explicit runway guidance provide durable funding for ongoing registrational programs and allow management to execute clinical milestones without immediate reliance on dilutive financings. This liquidity supports multi-year development timelines and strategic optionality.
Strategic Astellas CollaborationA deep partnership with Astellas shares development costs, provides near-term cash, and grants ex-US commercialization scale. Cost-sharing and milestone/royalty structures materially de-risk VIR-5500 development and extend Vir’s commercial reach without requiring full standalone commercialization infrastructure.
HDV Clinical & Regulatory MomentumStrong Phase 2 SOLSTICE results plus multiple regulatory designations and progressing registrational ECLIPSE trials create a durable path toward approval for an orphan indication. Regulatory support and staged pivotal data can accelerate review and payer conversations for a high‑value, limited‑patient market.
Bears Say
Revenue Collapse & Large LossesThe dramatic decline in revenue and sustained large net losses indicate structural reliance on partnerships and milestone funding rather than recurring product sales. Persistent negative profitability constrains internal reinvestment capacity and increases dependence on external capital and partner economics.
Persistent Cash BurnMaterial negative operating and free cash flow show that core operations do not yet generate net cash. Continued burn requires further milestone receipts, partnerships, or capital raises, which can dilute equity or shift strategic choices if key clinical readouts or collaborator payments are delayed.
Regulatory / Pivotal Execution RiskManagement’s need to combine multiple pivotal datasets lengthens timelines and raises the bar for regulatory success. Additional trials increase cost, trial execution risk, and dependency on enrollment and data quality, making commercial timing and cash flow realization more uncertain.
Vir Biotechnology News
VIR FAQ
What was Vir Biotechnology, Inc.’s price range in the past 12 months?
Vir Biotechnology, Inc. lowest stock price was $4.16 and its highest was $11.66 in the past 12 months.
What is Vir Biotechnology, Inc.’s market cap?
Vir Biotechnology, Inc.’s market cap is $1.48B.
When is Vir Biotechnology, Inc.’s upcoming earnings report date?
Vir Biotechnology, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 55 days.
How were Vir Biotechnology, Inc.’s earnings last quarter?
Vir Biotechnology, Inc. released its earnings results on May 06, 2026. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.096 by -$0.754.
Is Vir Biotechnology, Inc. overvalued?
According to Wall Street analysts Vir Biotechnology, Inc.’s price is currently Undervalued.
Does Vir Biotechnology, Inc. pay dividends?
Vir Biotechnology, Inc. does not currently pay dividends.
What is Vir Biotechnology, Inc.’s EPS estimate?
Vir Biotechnology, Inc.’s EPS estimate is 0.33.
How many shares outstanding does Vir Biotechnology, Inc. have?
Vir Biotechnology, Inc. has 168,651,980 shares outstanding.
What happened to Vir Biotechnology, Inc.’s price movement after its last earnings report?
Vir Biotechnology, Inc. reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.096. Following the earnings report the stock price went down -9.913%.
Which hedge fund is a major shareholder of Vir Biotechnology, Inc.?
Currently, no hedge funds are holding shares in VIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vir Biotechnology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.86 (94.02% Upside)
$20.86 (94.02% Upside)
Blogger Sentiment
Bullish
VIR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 48.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.68%
12-Months-Change
Fundamentals
Return on Equity
-53.31%
Trailing 12-Months
Asset Growth
-21.57%
Trailing 12-Months
Company Description
Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
VIR Company Deck
VIR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum: a large strategic collaboration with Astellas closed with immediate and near-term cash, meaningful capital raises, strong Phase 1 safety/early efficacy for VIR-5500, and highly differentiated Phase 2 HDV data with regulatory support and multiple registrational trials underway. Offsetting these positives are continued quarterly net losses, high R&D spend, the need for multiple pivotal datasets for filing in HDV, underdiagnosis in the target HDV population, and class-level safety/competitive risks for T cell engagers. On balance, the advances in clinical data, strategic partnerships, and strengthened balance sheet materially outweigh the near-term financial and execution risks.View all VIR earnings summariesVIR Stock 12 Month Forecast
Average Price Target
$20.86
▲(94.02% Upside)
Technical Analysis
Ownership Overview
10.10% Insiders
12.96% Mutual Funds
31.88% Other Institutional Investors
25.10% Public Companies and
Individual Investors